Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
← catalyst calendarNCT07511361 · readout ≤ 134 d
Sponsored by Kardigan, Inc. (industry) · KARD — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
140estimated
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-23 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hypertension
- Acute Severe Hypertension
- Hypertensive Emergency
- Hypertensive Urgency
Interventions
- Drug: Tonlamarsen
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptions
measured Baseline through Week 12
Part B: To assess the pharmacodynamic (PD) effect of tonlamarsen on plasma AGT levels
measured Week 4
Permalink · KARD's whole pipeline · Catalyst calendar · Every registered study · What changed